

Disclosures under Regulation 62 of the SEBI Listing Regulations				
Sr. No.	PARTICULARS AS PER LODR	YES/NO/NA	URL	REMARKS
1	(a) details of its business;	Yes	https://www.godreiseedsandgenetics.com/know-us	
2	(aa) composition of Board	Yes	https://www.godreiseedsandgenetics.com/board-of-directors	
3	(b) financial information including:	Yes	https://www.godreiseedsandgenetics.com/investors/listing-compliance	
	(i) notice of meeting of the board of directors where financial results shall be discussed;		https://www.godreiseedsandgenetics.com/pdf/listing-compliance/PRIORINTIMATIONGSGI.pdf	
	(ii) financial results, on conclusion of the meeting of the board of directors where the financial results were approved;		https://www.godreiseedsandgenetics.com/pdf/listing-compliance/NSEBMOUTCOME19012026RESULTS.pdf	
	(iii) complete copy of the annual report including balance sheet, profit and loss account, directors report, corporate governance report etc;		https://www.godreiseedsandgenetics.com/pdf/GSGI-Annual-Report-2025.pdf	
4	(c) contact information of the designated officials of the listed entity who are responsible for assisting and handling investor grievances;	Yes	https://www.godreiseedsandgenetics.com/investors/investor-information	
5	(d) email address for grievance redressal and other relevant details;	Yes	https://www.godreiseedsandgenetics.com/investors/investor-information	
6	(e) name of the debenture trustees with full contact details;	Yes	https://www.godreiseedsandgenetics.com/investors/investor-information	
7	(f) the information, report, notices, call letters, circulars, proceedings, etc concerning non-convertible redeemable preference shares or non convertible debt securities;	Yes	https://www.godreiseedsandgenetics.com/pdf/listing-compliance/GSGLNSEEGMPROCEEDINGS12082025.pdf	
8	(g) all information and reports including compliance reports filed by the listed entity;	Yes	https://www.godreiseedsandgenetics.com/pdf/listing-compliance/GSGL_SecurityCover_Dec312025.pdf	There are several compliances filed by the Company in this regard which is updated on the website. However, the recent compliance intimation is attached.
9	(h) information with respect to the following	NA		Company has not made any default till date
	i. default by issuer to pay interest on or redemption amount;			
	ii. failure to create a charge on the assets;			
10	(i) all credit ratings obtained by the entity for all its listed non-convertible securities, updated immediately upon any revision in the ratings	Yes	https://www.godreiseedsandgenetics.com/pdf/credit-ratings/Rating_from_Credit_Rating_Agencies.pdf	
11	(j) statements of deviation(s) or variation(s) as specified in sub-regulation (7) and sub-regulation (7A) of regulation 52	Yes	https://www.godreiseedsandgenetics.com/pdf/listing-compliance/GSGLNSE527DEC312025.pdf	
12	(k) Annual Return as provided under section 92 of the Companies Act, 2013 and the rules made thereunder	NA		This is not applicable as the Company got listed on July 31, 2025
Additional Disclosures:				
13	(a) composition of the various committees of the board of directors;	NA	https://www.godreiseedsandgenetics.com/investors/board-committees	Not Applicable since the company has ceased to be a high value debt listed entity under revised definition from January 20, 2026. However, the details are available on the website
14	(b) terms and conditions of appointment of independent directors;	NA	https://www.godreiseedsandgenetics.com/pdf/codes-policies/Roles_and_Responsibilities_of_Independent_Director.pdf	Not Applicable since the company has ceased to be a high value debt listed entity under revised definition from January 20, 2026. However, the details are available on the website
15	(c) code of conduct of the board of directors and senior management personnel;	NA	https://www.godreiseedsandgenetics.com/pdf/codes-policies/GSGL_Code_of_Conduct_Policy.pdf	Not Applicable since the company has ceased to be a high value debt listed entity under revised definition from January 20, 2026. However, the details are available on the website
16	(d) details of establishment of vigil mechanism/ whistle blower policy	NA	https://www.godreiseedsandgenetics.com/pdf/codes-policies/GSGL-Whistle-Blower-Policy.pdf	Not Applicable since the company has ceased to be a high value debt listed entity under revised definition from January 20, 2026. However, the details are available on the website
17	(e) criteria of making payments to non-executive directors, if the same has not been disclosed in the annual report;	NA	https://www.godreiseedsandgenetics.com/pdf/codes-policies/GSGL-NRC-Policy.pdf	Not Applicable since the company has ceased to be a high value debt listed entity under revised definition from January 20, 2026. However, the details are available on the website
18	(f) secretarial compliance report	NA		Not Applicable since the company has ceased to be a high value debt listed entity under revised definition from January 20, 2026.
19	(g) policy on dealing with related party transactions;	NA	https://www.godreiseedsandgenetics.com/pdf/codes-policies/GSGL_RPT_Policy.pdf	Not Applicable since the company has ceased to be a high value debt listed entity under revised definition from January 20, 2026. However, the details are available on the website
20	(h) policy for determining 'material' subsidiaries;	NA	https://www.godreiseedsandgenetics.com/pdf/codes-policies/Policy_for_determining_material_subsidary.pdf	Not Applicable since the company has ceased to be a high value debt listed entity under revised definition from January 20, 2026. However, the details are available on the website
21	(i) details of familiarization programmes imparted to independent directors including the following details:-	NA	https://www.godreiseedsandgenetics.com/pdf/listing-compliance/Familiarisation_Programme.pdf	Not Applicable since the company has ceased to be a high value debt listed entity under revised definition from January 20, 2026. However, the details are available on the website
	i. number of programmes attended by the independent directors (during the year and on a cumulative basis till date),			
	ii. number of hours spent by the independent directors in such programmes (during the year and on cumulative basis till date), and			
	iii. other relevant details			